Milan Sonneveld

Milan Sonneveld is a researcher at Erasmus MC in the Department of Gastroenterology & Hepatology, where he focuses on advancing the understanding and treatment of chronic hepatitis B. His work is central to identifying predictors of disease flares after antiviral therapy cessation and exploring strategies for functional cure.

• Institution: Erasmus MC
• Department: Gastroenterology & Hepatology

His research interests include chronic hepatitis B, virological biomarkers (HBsAg, HBV DNA, HBcrAg), nucleos(t)ide analogue withdrawal, peginterferon therapy, and the intersection of metabolic liver disease with viral hepatitis. He investigates how metabolic dysfunction affects liver stiffness in HBV patients and seeks to identify high-risk individuals for severe flares post-treatment.

The recent trend in his publications emphasizes clinical cohort studies, pooled analyses, and translational research aimed at improving outcomes in chronic hepatitis B. His work frequently appears in leading journals such as the Journal of Hepatology and Liver International, reflecting strong international collaboration and impact.

While no specific awards are listed in the provided text, his contributions to high-impact studies like the RETRACT-B study and multiple peer-reviewed articles indicate significant recognition in the hepatology community.

Dr. Sonneveld collaborates extensively with senior researchers including Harry L.A. Janssen and Bruno E. Hansen. He participates in major research initiatives and global cohort studies but no formal advising or grant leadership is explicitly mentioned in the current data. He contributes to both primary research and editorial commentary in the field.

He is part of a dynamic research network at Erasmus MC focused on viral hepatitis, contributing to a robust fingerprint of expertise in HBV virology, treatment strategies, and disease monitoring.